Blueprint executive chairman Jeff Albers and Blueprint CEO Kate Haviland (Brad Bahner Photography)
Blueprint Medicines slips as it changes endpoint for trial in aim to greatly broaden Ayvakit label
Blueprint is forging ahead on its slow crawl to broaden its market for Ayvakit.
Having nabbed its fourth approval for the drug in 2021 for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
